I'll be out of the office for an extra-long holiday weekend, so I'm emptying out the blog inbox before I go.

Nick Stavriotis sent an email to clarify his previous incomplete statementregarding the FDA's "overrule" of the Dendreon Provenge advisory committee recommendation: